[{"id":"fa8a97f1-cabc-4bf2-8fa9-208f8cb378d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04977024","created_at":"2021-07-26T17:53:28.425Z","updated_at":"2024-07-02T16:35:30.225Z","phase":"Phase 2","brief_title":"SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer","source_id_and_acronym":"NCT04977024","lead_sponsor":"GeoVax, Inc.","biomarkers":" CD8 • PD-1 • IFNG • CD4 • TNFRSF9 • ACE2","pipe":" | ","alterations":" CD8 expression","tags":["CD8 • PD-1 • IFNG • CD4 • TNFRSF9 • ACE2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 09/27/2021","start_date":" 09/27/2021","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2023-11-06"},{"id":"f9d52912-1574-45da-92ca-3ef55cf34e4b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04542863","created_at":"2023-03-14T18:02:32.751Z","updated_at":"2024-07-02T16:35:51.969Z","phase":"","brief_title":"The Molecular Imaging Research of F-18 Labeled DX600 PET Probe","source_id_and_acronym":"NCT04542863","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" ACE2","pipe":"","alterations":" ","tags":["ACE2"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/11/2020","start_date":" 09/11/2020","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-03-29"},{"id":"0810c422-f1d5-4539-9aed-94fb7b0e12f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04422457","created_at":"2023-03-14T18:02:25.026Z","updated_at":"2024-07-02T16:36:07.074Z","phase":"","brief_title":"Specific Molecular Imaging of DX600 Labeled by PET Radionuclide Targeting ACE2 in Patients","source_id_and_acronym":"NCT04422457","lead_sponsor":"Beijing Cancer Hospital","biomarkers":" ACE2","pipe":"","alterations":" ","tags":["ACE2"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 06/13/2020","start_date":" 06/13/2020","primary_txt":" Primary completion: 03/01/2022","primary_completion_date":" 03/01/2022","study_txt":" Completion: 03/01/2022","study_completion_date":" 03/01/2022","last_update_posted":"2022-07-20"}]